人类与小鼠肝细胞癌的免疫生物学:基本概念与治疗意义
综述总结小鼠模型基础研究与人类临床实践对肝脏及肝细胞癌(HCC)肿瘤免疫学的认识。HCC受免疫系统强烈影响,近期发现可部分受益于免疫检查点抑制剂治疗。HCC肿瘤免疫依赖多种遗传与环境因素共同塑造促癌炎症和免疫功能障碍,这些过程控制HCC恶性进展与治疗反应。
要点
- HCC受免疫系统强烈影响,近期发现可部分受益于免疫检查点抑制剂治疗。
- HCC肿瘤免疫依赖遗传与环境因素共同塑造促癌炎症和免疫功能障碍。
- 促癌炎症与免疫功能障碍是控制HCC恶性进展及治疗反应的关键过程。
核心结论
- HCC受免疫系统强烈影响,近期发现可部分受益于免疫检查点抑制剂治疗。
研究设计与样本
- 综述总结小鼠模型基础研究与人类临床实践对肝脏及HCC肿瘤免疫学的认识。
主要发现
- HCC肿瘤免疫依赖多种遗传与环境因素共同塑造促癌炎症和免疫功能障碍。
- 促癌炎症与免疫功能障碍是控制HCC恶性进展及治疗反应的关键过程。
临床怎么用
- 临床前与临床发现提示免疫调节是HCC发展的重要因素,并解释HCC靶向免疫治疗的基础。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Basic and clinical studies have demonstrated the efficacy of immunotherapy, a technical and conceptual breakthrough that has revolutionised cancer treatment. Hepatocellular carcinoma (HCC), a deadly malignancy with aetiologic diversity and a chronic course, is strongly influenced by the immune system, and was recently found to partially benefit from immune-checkpoint inhibitor therapy. Notably, HCC onco-immunology depends on diverse genetic and environmental factors that together shape cancer-promoting inflammation and immune dysfunction - critical processes that control HCC malignant progression and response to therapy. Herein, we summarise the current understanding of liver and HCC onco-immunology obtained through basic studies with mouse models and clinical practice in humans. In particular, we discuss preclinical and clinical findings that implicate immunomodulation as a major factor in HCC development and explain the basis for HCC-targeting immunotherapy.
引用
- Hou J, Zhang H, Sun B, et al. The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications. J Hepatol. 2019. PMID: 31449859. doi:10.1016/j.jhep.2019.08.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。